Study the Relationship Between Obesity and Hepatitis C Replication
Status:
Withdrawn
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Patients with chronic hepatitis C viral infection (HCV) and with a BMI greater than 25Kg/m2
are refractory to medical treatment. Also, HCV replication seems to be affected when modeling
insulin resistance in replicon cell culture systems.
PPARg -agonist (Pioglitazone) is effective in controlling liver inflammation in obese
subjects with non-alcoholic steatohepatitis (NASH) and also improving insulin sensitivity.
Therefore, we hypothesize that improving insulin resistance and /or inflammation may affect
HCV replication and viral kinetics. Independently of PPARg pathways, Prednisone may increase
HCV viral kinetics. .